Aditum Bio

Tempero Bio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for treating and preventing substance use disorders. The company aims to address the challenges faced by individuals struggling with addiction, providing innovative treatments that facilitate recovery and improve overall health outcomes. By specializing in this critical area of healthcare, Tempero Bio seeks to make a meaningful impact on the lives of patients affected by substance use disorders and related conditions.

Hubpay is an independently regulated provider of cross-border money services aimed at enhancing financial inclusion in emerging markets. The company operates an online financial platform that facilitates overseas money transfers, offering services such as competitive foreign exchange, multi-currency accounts, and payment systems for suppliers, partners, and employees. By leveraging data science, Hubpay delivers accessible and affordable financial solutions, enabling users to conduct instant money transfers with ease. This allows businesses and individuals to manage their finances effectively, regardless of their income level, and concentrate on their growth without the stress of complex financial transactions.

Via Nova Therapeutics is a biopharmaceutical company focused on discovering and developing therapeutics for acute and subacute viral infections that lack effective treatments. The company’s portfolio includes antiviral programs targeting significant respiratory viruses such as influenza, adenoviruses, and rhinoviruses, as well as human polyomaviruses, which can cause severe illness in immunocompromised individuals. By concentrating on the fundamental mechanisms of viral replication, Via Nova Therapeutics aims to facilitate the development of novel therapeutics not only for its current targets but also for a broader range of viral infections.

Versanis Bio is a biopharmaceutical company focused on discovering and developing innovative medicines for medical conditions commonly affecting older adults. The company is advancing Bimagrumab, a human monoclonal antibody that targets activin type II receptors, effectively blocking ligands such as activin A and myostatin. Bimagrumab has undergone extensive clinical evaluation in over a dozen trials with more than 1,500 participants, demonstrating its ability to induce significant fat loss while preserving lean mass. Additionally, treatment with Bimagrumab has shown improvements in HbA1c levels and other cardiometabolic parameters, thereby assisting overweight and obese adults in achieving and maintaining a healthier body composition.

Anteris Bio is developing a new therapy for the treatment of renal disease.